TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Safety and efficacy of olutasidenib in patients with IDH1-mutated relapsed/refractory AML

By Dylan Barrett

Share:

Dec 29, 2022

Learning objective: After reading this article, learners will be able to cite a new development in the treatment of AML.


Olutasidenib is a selective, oral, small molecule inhibitor of isocitrate dehydrogenase 1 (IDH1) that has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory (R/R) IDH1-mutated acute myeloid leukemia (AML).

Olutasidenib was assessed for safety and efficacy in the phase I/II 2102-HEM-101 trial (NCT02719574), topline results from which have been previously covered by the AML Hub. Following positive results from the phase I portion of this trial, Cortes1 presented phase II results at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, which we are pleased to summarize below.

Study design and patients

In this open-label, multicenter study, 153 patients with R/R AML and a median age of 71.0 years received ≥1 dose of olutasidenib monotherapy (phase I identified a dose of 150 mg, twice daily, in continuous 28-day cycles). Of these patients, 66% had de novo AML and 34% had secondary AML. The majority (73%) of patients had intermediate cytogenetics, with 17% and 4% having poor and favorable cytogenetics, respectively. The primary endpoint was complete remission (CR) plus CR with partial hematologic recovery (CRh) rate (CR+CRh). Secondary endpoints included overall response rate, duration of CR+CRh, duration of overall response, rate of transfusion independence, and overall survival (OS).

Results

Response rates

Of the 147 patients evaluable for response, the:

  • CR+CRh rate was 35% (Table 1);
  • median time to CR+CRh response was 1.9 months (range, 0.9–5.6); and
  • median duration of CR+CRh response was 25.9 months (95% CI, 13.5–not evaluable).

Table 1. Response rates in patients who received olutasidenib monotherapy*

CR, complete remission; CRh, CR with partial hematologic recovery; CRi, CR with incomplete recovery; MLFS, morphologic leukemia-free state; ORR, overall response rate; PR, partial remission.
*Adapted from Cortes.1

Response, %

Patients
(n = 147)

CR

32

CRh

3

CR+CRh

35

CRi

10

PR

2

MLFS

1

ORR

48

Non-responders

35

Survival outcomes

The median OS was 11.6 months (95% confidence interval [CI], 8.9–15.5; n = 153) and the estimated 18-month survival among patients who achieved CR+CRh was 78%. Within the different response categories, the median OS was:

  • not reached (95% CI, 22.8–not reached) among patients who achieved CR+CRh;
  • 13.7 months (95% CI, 6.0–not reached) among other responders; and
  • 4.0 months (95% CI, 3.2–5.8) among non-responders.

Transfusion independence

At baseline, 86 patients were platelet and/or red blood cell transfusion dependent. Among these patients, 34% became transfusion-independent by 56 days, across all response groups. Transfusion-independence rates were higher among patients who achieved CR+CRh than among other responders.

Safety

Of the 153 patients, 14% experienced differentiation syndrome (Table 2), which led to one death. Overall, 31% of patients died, mostly due to the progression of AML (14%). Treatment was discontinued due to treatment-emergent adverse events in 31% of patients, the majority due to disease progression (14%).

Table 2. Treatment-emergent adverse events in patients who received olutasidenib*

ALT, alanine transaminase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase.
*Adapted from Cortes.1

Adverse events, %

All grades (>5%)

Grade 3 or 4 (>2%)

Any adverse event

73

39

Nausea

23

0

Differentiation syndrome

14

8

Leukocytosis

13

5

Increased ALT

8

3

Constipation

8

0

Fatigue

7

1

Vomiting

7

0

Anemia

6

5

Increased AST

6

2

Thrombocytopenia

5

4

Neutropenia

5

5

GGT increased

5

5

Hepatic enzyme increased

4

3

Conclusion

Olutasidenib demonstrated clinical efficacy with a manageable safety profile in this population of patients with R/R IDH1-mutated AML. Clinical responses were durable and transfusion independence was achieved across all response groups.

References

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content